Epoetin beta is a Recombinant Protein owned by F. Hoffmann-La Roche, and is involved in 62 clinical trials, which were completed.

Epoetin Beta was an ESA (Erythropoiesis-Stimulating Agent). It can reduce transfusions and increase hemoglobin (Hb) levels in patients with chemotherapy-induced anemia (CIA). Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation. Glycoproteinous hematopoietic factor basically has the same chemical structure as natural human urinary erythropoietin, and that it facilitates the differentiation and proliferation of the precursor cells of erythroblasts in the bone marrow into red blood cells.

The revenue for Epoetin beta is expected to reach a total of $1.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Epoetin beta NPV Report.

Epoetin beta is currently owned by F. Hoffmann-La Roche.

Epoetin beta Overview

Epoetin Beta (Epoch, NeoRecormon, Rocco Man, LUO Man, Recormon) is a hemopoietic factor, acts as anti-anemic agent. It is formulated as injectable powder for solution and injectable solution for subcutaneous, intravenous route of administration. It is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients, prevention of anaemia of prematurity in infants with a birth weight of 750 to 1500 g and a gestational age of less than 34 weeks, treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy, increasing the yield of autologous blood from patients in a pre-donation programme.

F. Hoffmann-La Roche Overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.

Quick View – Epoetin beta

Report Segments
  • Innovator (NME)
Drug Name
  • Epoetin beta
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Hematological Disorders
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.